Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system
10.11665/j.issn.1000-5048.20160505
- VernacularTitle:去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展
- Author:
GAO Yuanyue
1
;
LIU Aiyun
;
SHEN Jiajia
;
DING Ya
Author Information
1. 中国药科大学药物质量与安全预警教育部重点实验室
- Publication Type:Journal Article
- Keywords:
asialoglycoprotein receptor;
targeted liver cancer therapy;
prodrug;
drug carrier;
gene therapy
- From:
Journal of China Pharmaceutical University
2016;47(5):537-542
- CountryChina
- Language:Chinese
-
Abstract:
Asialoglycoprotein receptor(ASGPR)is a receptor expressed mainly on the surface of liver sinusoidal and basolateral cells. It can exclusively identity, combine and clear desialylated glycoproteins with exposed non-reducing D-galactose(Gal)or nacetylgalactosamine(GalNAc)as end groups. Based on this characteristic, ASGPR-mediated targeted liver cancer therapy has drawn extensive attention. The present review details the latest research progress of this field in three aspects, glycosylated prodrug, small molecular nanocarriers, and glycosylated gene complex therapy system.
